Drug for blood clotting problems in severe infections
Part of Infections clinical trials.
This trial tests an experimental drug called nafamostat mesilate to help control blood clotting problems in people with severe infections (sepsis). It aims to reduce the risk of abnormal blood clots that can harm organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with sepsis, a severe infection that affects your whole body.
- You must be 18 years or older and not be pregnant or breastfeeding.
- You must not have active bleeding or a high risk of bleeding right now.
- You must not have taken certain blood-thinning medicines (like aspirin, warfarin, or other anticoagulants) recently.
- You must not be in the intensive care unit (ICU) for less than 24 hours or have had CPR in the past week.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two blood-thinning drugs (nafamostat and heparin) that are given during dialysis for kidney failure caused by sepsis. The goal is to see which drug is safer and helps keep the dialysis filter working better.
This study tests a new medicine called BAY 3389934 to see if it's safe and what dose works best for people with sepsis and blood clotting issues. The goal is to improve blood clotting and help you recover from the infection.
This trial tests a new treatment to protect and repair the layer of cells lining your blood vessels (glycocalyx) during sepsis. It aims to improve recovery from severe infections.
This study compares two ways to prevent blood clots during kidney dialysis in people with sepsis-related kidney failure. The goal is to see which method is safer and works better to keep the dialysis filter working properly.
This trial studies whether combining anisodamine (a medicine for certain gut/smooth-muscle effects) with a low-molecular-weight blood thinner helps treat sepsis. It may be aimed at improving outcomes compared with standard care, but eligibility depends on safety factors like bleeding risk and organ function.
This trial tests an experimental drug called NAI for people in the intensive care unit (ICU) with severe infections like sepsis. It aims to boost your immune system to help fight the infection and improve recovery.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.